Company intelligence / Profile preview

AIKO

Portland, Maine, United Statesaiko.com ↗

Ownership: Private
Development stage: Other

Overview

AIKO Biotechnology developed novel small molecule opioid antagonists and modulators designed to treat pain and mitigate the side effects of prescription opioids. Their lead compound, AIKO-150, completed two Phase 1 clinical trials demonstrating high potency in blocking opioid-induced gastrointestinal effects without interfering with analgesia. The company also worked on analogs such as naltrexol and naltrexamine. As of May 2025, the company is dissolved and its pipeline discontinued.

Therapeutic areas: PsychiatryGastroenterologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

None reported in public sources.

Beyond the preview

Go deeper on AIKO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIKO.

Explore the full profile